BONESUPPORT’s 510(k) submission for Cerament bone void filler to include an indication for spinal interbody fusion received FDA clearance to market. As previously stated, U.S. market introduction for the application is slated by end of 2025.
Cerament is an injectable, moldable and drillable synthetic bone void filler comprising 40% hydroxyapatite, 60% calcium sulfate and the radio-contrast agent iohexol.
The ratio of hydroxyapatite and calcium sulfate is designed to enable Cerament to resorb at the same rate that bone forms. Calcium sulfate acts as a resorbable carrier for hydroxyapatite, and hydroxyapatite is highly osteoconductive, promoting bone ingrowth.
The characteristics of Cerament make it suitable for minimally invasive surgery and open procedures where bone remodeling is required.
BONESUPPORT’s 510(k) submission for Cerament bone void filler to include an indication for spinal interbody fusion received FDA clearance to market. As previously stated, U.S. market introduction for the application is slated by end of 2025.
Cerament is an injectable, moldable and drillable synthetic bone void filler comprising 40%...
BONESUPPORT’s 510(k) submission for Cerament bone void filler to include an indication for spinal interbody fusion received FDA clearance to market. As previously stated, U.S. market introduction for the application is slated by end of 2025.
Cerament is an injectable, moldable and drillable synthetic bone void filler comprising 40% hydroxyapatite, 60% calcium sulfate and the radio-contrast agent iohexol.
The ratio of hydroxyapatite and calcium sulfate is designed to enable Cerament to resorb at the same rate that bone forms. Calcium sulfate acts as a resorbable carrier for hydroxyapatite, and hydroxyapatite is highly osteoconductive, promoting bone ingrowth.
The characteristics of Cerament make it suitable for minimally invasive surgery and open procedures where bone remodeling is required.
Copy to clipboard 
